Surveillance in Patients with Barrett's Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis

Clinical and Translational Gastroenterology

Volumn 6, Issue , 2015, Pages

  Qiao, Yao ^a   Hyder, Ayaz ^a   Bae, Sandy J ^a   Zarin, Wasifa ^a   O'Neill, Tyler J ^a   Marcon, Norman E ^b,c   Stein, Lincoln ^d   Thein, Hla Hla ^a,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DYSPLASIA; ESOPHAGUS PERFORATION; FOLLOW UP; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 84949683970     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.58     Document Type: Review

References (79)

1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797.
2. di Pietro M, Chan D, Fitzgerald RC et al. Screening for Barrett's esophagus. Gastroenterology 2015; 148: 912-923.
3. Phillips WA, Lord RV, Nancarrow DJ et al. Barrett's esophagus. J Gastroenterol Hepatol 2011; 26: 639-648.
4. Otterstatter MC, Brierley JD, De P et al. Esophageal cancer in Canada: trends according to morphology and anatomical location. Can J Gastroenterol 2012; 26: 723-727.
5. Fountoulakis A, Zafirellis KD, Dolan K et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004; 91: 997-1003.
6. Bright T, Schloithe A, Bull JA et al. Outcome of endoscopy surveillance for Barrett's oesophagus. ANZ J Surg 2009; 79: 812-816.
7. Chang LC, Oelschlager BK, Quiroga E et al. Long-term outcome of esophagectomy for highgrade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg 2006; 10: 341-346.
8. Corley DA, Levin TR, Habel LA et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640.
9. Bhat SK, McManus DT, Coleman HG et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 2015; 64: 20-25.
10. Corley DA, Mehtani K, Quesenberry C et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013; 145: 312-319 e1.
11. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-186.
12. Alcedo J, Ferrandez A, Arenas J et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus 2009; 22: 239-248.
13. Green J. Complications of gastrointestinal endoscopy. BSG Guidelines in Gastroenterology November 2006. Available from http://www.bsg.org.uk/pdf-word-docs/complications.pdf Accessed 23 July 2015.
14. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
15. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available from http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp Accessed 22 April 2015.
16. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
18. Thacker SB. Meta-analysis. A quantitative approach to research integration. JAMA 1988; 259: 1685-1689.
19. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
21. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org Accessed 22 April 2015.
22. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Borenstein M, Hedges L, Higgins J et al. Comprehensive Meta-Analysis Version 2. Biostat: Englewood, NJ, 2005: 104.
24. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573.
25. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624.
26. Organization for Economic Co-Operation and Development. PPPs and exchange rates. 2015. Available from http://stats.oecd.org/Index.aspx?DatasetCode =SNA-TABLE4 Accessed 22 April 2015.
27. United States Department of Labor Bureau of Labor Statistics. Consumer Price Index, All Urban Consumers, US city average, Medical care services. Available from http://data.bls. gov/cgi-bin/surveymost?cu. Accessed 1 December 2015.
28. Ajumobi A, Bahjri K, Jackson C et al. Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci 2010; 55: 1615-1621.
29. Bani-Hani K, Sue-Ling H, Johnston D et al. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 2000; 12: 649-654.
30. Nilsson J, Skobe V, Johansson J et al. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol 2000; 35: 10-16.
31. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989; 34: 1336-1339.
32. Hameeteman W, Tytgat GN, Houthoff HJ et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
33. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32: 1441-1446.
34. Williamson WA, Ellis FH Jr, Gibb SP et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151: 2212-2216.
35. Iftikhar SY, James PD, Steele RJC et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-1158.
36. Ortiz A, Martinez de Haro LF, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996; 83: 274-278.
37. Ferraris R, Bonelli L, Conio M et al. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 1997; 9: 881-885.
38. Katz D, Rothstein R, Schned A et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-541.
39. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 1252-1255.
40. Hage M, Siersema PD, van Dekken H et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175-1179.
41. Switzer-Taylor V, Schlup M, Lübcke R et al. Barrett's esophagus: a retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol 2008; 23: 1362-1367.
42. Sharma P, Morales TG, Bhattacharyya A et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92: 2012-2016.
43. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572.
44. Peters JH, Clark GW, Ireland AP et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-821 discussion 21-2.
45. Abdalla M, Dhanekula R, Greenspan M et al. Dysplasia detection rate of confirmatory EGD in nondysplastic Barrett's esophagus. Dis Esophagus 2014; 27: 505-510.
46. Olithselvan A, Gorard DA, McIntyre AS. A surveillance programme for Barrett's oesophagus in a UK general hospital. Eur J Gastroenterol Hepatol 2007; 19: 305-309.
47. von Rahden BH, Stein HJ, Weber A et al. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Dis Esophagus 2008; 21: 685-689.
48. Vieth M, Schubert B, Lang-Schwarz K et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006; 38: 1201-1205.
49. Fitzgerald RC, Saeed IT, Khoo D et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46: 1892-1898.
50. Streitz JM Jr., Ellis FH Jr., Tilden RL et al. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911-915.
51. Wright TA, Gray MR, Morris AI et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39: 574-579.
52. Roberts KJ, Harper E, Alderson D et al. Long-term survival and cost analysis of an annual Barrett's surveillance programme. Eur J Gastroenterol Hepatol 2010; 22: 399-403.
53. Aldulaimi DM, Cox M, Nwokolo CU et al. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005; 17: 943-950.
54. Yousef F, Cardwell C, Cantwell MM et al. The incidence of esophageal cancer and highgrade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-249.
55. Thomas T, Abrams KR, De Caestecker JS et al. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007; 26: 1465-1477.
56. Sikkema M, de Jonge PJ, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235-244 quiz e32.
57. Timmer MR, Martinez P, Lau CT et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut 2015; doi:10.1136/ gutjnl-2015-309642.
58. Robertson CS, Mayberry JF, Nicholson DA et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75: 760-763.
59. Verbeek RE, Leenders M, Ten Kate FJ et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol 2014; 109: 1215-1222.
60. Fitzgerald RC, Di Pietro M, Ragunath K et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42.
61. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-1895.
62. Boyer J, Robaszkiewicz M. Guidelines of the French Society of Digestive Endoscopy: monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy 2000; 32: 498-499.
63. Van Sandick JW, Van Lanschot JJB, Kuiken BW et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-222.
64. Teodori L, Gohde W, Persiani M et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34: 257-263.
65. Schoenfeld P, Johnston M, Piorkowski M et al. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol 1998; 93: 906-910.
66. Rudolph RE, Vaughan TL, Storer BE et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132: 612-620.
67. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-1676.
68. Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98: 1931-1939.
69. Hillman LC, Chiragakis L, Clarke AC et al. Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 2003; 18: 526-533.
70. Basu KK, Pick B, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 2004; 16: 171-175.
71. Meining A, Ott R, Becker I et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only-what is the clinical significance? Gut 2004; 53: 1402-1407.
72. Murphy SJ, Dickey W, Hughes D et al. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland. Eur J Gastroenterol Hepatol 2005; 17: 1029-1035.
73. Dulai GS, Shekelle PG, Jensen DM et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 2005; 100: 775-783.
74. Oberg S, Wenner J, Johansson J et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242: 49-54.
75. Gladman L, ChapmanW, Iqbal TH et al. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 2006; 18: 271-276.
76. Musana AK, Resnick JM, Torbey CF et al. Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol 2008; 103: 516-524.
77. Martinek J, Benes M, Brandtl P et al. Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study. Endoscopy 2008; 40: 711-716.
78. Ramus JR, Gatenby PA, Caygill CP et al. Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. Eur J Gastroenterol Hepatol 2009; 21: 636-641.
79. Parrilla P, Martinez de Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298.